Home > Oncology > ESMO 2022 > Trend to improved survival with first-line pembrolizumab plus CRT in locally advanced head-and-neck squamous cell carcinoma

Trend to improved survival with first-line pembrolizumab plus CRT in locally advanced head-and-neck squamous cell carcinoma

Presented By
Dr Jean-Pascal Machiels, Cliniques Universitaires Saint-Luc, Belgium
Conference
ESMO 2022
Trial
Phase 3, KEYNOTE-412
First-line pembrolizumab plus chemoradiotherapy (CRT) is associated with a favourable trend towards improved even-free survival (EFS) versus placebo in patients with locally advanced head and neck squamous cell carcinoma, first results of the KEYNOTE-412 trial show. Standard-of-care for patients with unresected locally advanced head-and-neck squamous cell carcinoma (LA-HNSCC) is concurrent chemoradiotherapy (CRT) with high-dose cisplatin [1]. However, less than 50% of patients remain free of disease at 3 years and the 5-year overall survival (OS) rate is about 50% [2]. Recently, pembrolizumab (with or without chemotherapy) was shown to improve survival in patients with recurrent or metastatic HNSCC [3]. The randomised, double-blind, phase 3 KEYNOTE-412 study (NCT03040999) investigated the efficacy and safety of pembrolizumab plus CRT versus placebo plus CRT in pat...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on